Compare TG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | CDXS |
|---|---|---|
| Founded | 1988 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Major Chemicals |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.4M | 256.3M |
| IPO Year | 1994 | 2008 |
| Metric | TG | CDXS |
|---|---|---|
| Price | $7.89 | $1.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 157.8K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | 43.82 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $800,821,000.00 | $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | $23.47 | ★ N/A |
| Revenue Growth | 8.29 | ★ 32.30 |
| 52 Week Low | $6.25 | $0.96 |
| 52 Week High | $10.53 | $3.12 |
| Indicator | TG | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 38.78 |
| Support Level | $7.24 | $1.57 |
| Resistance Level | $8.20 | $1.92 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 31.84 | 69.64 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.